A Study to Evaluate Patient Characteristics and Treatment Patterns Among Rheumatoid Arthritis Patients

Inclusion Criteria

• •first pharmacy claim for Tofacitinib and then Etanercept or Adalimumab between Jan 2014 and Sep 2016 represents the index claim
• •First, select patients receiving ≥1 Tofacitinib pharmacy claim (Jan 2014-Sep 2016) who did not have a Tofacitinib claim anytime prior to index
• •Patients do have \>1 advanced therapy filled on index date
• •Physician diagnosis of Rheumatoid Arthritis (in any position) during the 1-year pre-index period, or on the index date
• •Age 18+ years at index